Background-Crohn's disease (CD) and ulcerative colitis (UC) are associated with expression differences in genes involved in immune function, wound healing, and tissue remodeling. MicroRNAs (miRNAs) are small, noncoding RNAs that act as potent negative regulators of gene expression and are differentially expressed in chronic inflammatory diseases, including UC. We examined the expression of miRNAs in tissues from different intestinal regions and in patients with active ileal and colonic CD.
Background
Crohn's disease (CD) and ulcerative colitis (UC) result from pathophysiologically distinct dysregulated immune responses, as evidenced by the preponderance of differing immune cell mediators and circulating cytokine expression profiles. MicroRNAs (miRNAs) are small, noncoding RNAs that act as negative regulators of gene expression and have an increasingly recognized role in immune regulation. We hypothesized that differences in circulating immune cells in CD and UC patients are reflected by altered miRNA expression and that miRNA expression patterns can distinguish CD and UC from normal healthy individuals.
Methods
Peripheral blood was obtained from patients with active CD, inactive CD, active UC, inactive UC and normal healthy adults. Total RNA was isolated and miRNA expression assessed using miRNA microarray and validated by mature miRNA quantitative RT-PCR.
Results
Five miRNAs were significantly increased and two miRNAs (149* and miRplus-F1065) were significantly decreased in the blood of active CD patients as compared to healthy controls. Twelve miRNAs were significantly increased and miRNA-505* was significantly decreased in the blood of active UC patients as compared to healthy controls. Ten miRNAs were significantly increased and one miRNA was significantly decreased in the blood of active UC patients as compared to active CD patients.
Conclusions
Peripheral blood miRNAs can be used to distinguish active CD and UC from healthy controls. The data support the evidence that CD and UC are associated with different circulating immune cells types and that the differential expression of peripheral blood miRNAs may form the basis of future diagnostic tests for IBD.
Colonic microbiota ferment non-absorbed dietary fiber to produce prodigious amounts of short chain fatty acids (SCFAs) that benefit the host through a myriad of metabolic, trophic, and chemopreventative effects. The chemopreventative effects of the SCFA butyrate are, in part, mediated through induction of p21 gene expression. In this study, we assessed the role of microRNA(miRNA) in butyrate's induction of p21 expression. The expression profiles of miRNAs in HCT-116 cells and in human sporadic colon cancers were assessed by microarray and quantitative PCR. Regulation of p21 gene expression by miR-106b was assessed by 3′ UTR luciferase reporter assays and transfection of specific miRNA mimics. Butyrate changed the expression of 44 miRNAs in HCT-116 cells, many of which were aberrantly expressed in colon cancer tissues. Members of the miR-106b family were decreased in the former and increased in the latter. Butyrate-induced p21 protein expression was dampened by treatment with a miR-106b mimic. Mutated p21 3′UTR-reporter constructs expressed in HCT-116 cells confirmed direct miR-106b targeting. Butyrate decreased HCT-116 proliferation, an effect reversed with the addition of the miR-106b mimic. We conclude that microbe-derived SCFAs regulate host gene expression involved in intestinal homeostasis as well as carcinogenesis through modulation of miRNAs.
Background and aim: Macrophage inflammatory protein 3α (MIP-3α) is a recently described lymphocyte directed C-C chemokine expressed predominately at extralymphoid sites, including the intestine. The aim of this study was to determine whether colonic epithelial cells produce MIP-3α and whether its expression is upregulated in inflammatory bowel disease. Methods and results: We found that interleukin 1β and tumour necrosis factor α dose dependently stimulated MIP-3α production in Caco-2 and HT-29 intestinal epithelial cells. In cytokine treated Caco-2 and HT-29 cells, a significant increase in MIP-3α protein production was observed after three hours and continued for at least 24 hours. Analysis of colonic tissues by quantitative real time polymerase chain reaction and ELISA revealed significantly elevated MIP-3α mRNA levels (7.9-fold; p<0.05) and protein levels (8.9-fold; p<0.05) in Crohn's disease compared with controls or ulcerative colitis. MIP-3α immunoreactivity in normal colon and inflammatory bowel disease was principally associated with crypt and surface epithelial cells. Moreover, MIP-3α protein levels were elevated in primary epithelial cells isolated from patients with inflammatory bowel disease. Conclusions: These findings indicate that increased enterocyte MIP-3α production may play an important role in lymphocyte activation and recruitment to the colonic epithelium in Crohn's disease and ulcerative colitis.
Background & Aims
The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and
Crohn’s disease (CD) cause significant morbidity and are increasing in
prevalence among all populations, including African Americans. More than 200
susceptibility loci have been identified in populations of predominantly European
ancestry, but few loci have been associated with IBD in other ethnicities.
Methods
We performed 2 high-density, genome-wide scans comprising 2345 cases of African
Americans with IBD (1646 with CD, 583 with UC, and 116 inflammatory bowel disease
unclassified [IBD-U]) and 5002 individuals without IBD (controls,
identified from the Health Retirement Study and Kaiser Permanente database).
Single-nucleotide polymorphisms (SNPs) associated at P<5.0×10−8 in
meta-analysis with a nominal evidence (P<.05) in each scan were considered to have
genome-wide significance.
Results
We detected SNPs at HLA-DRB1, and African-specific SNPs at ZNF649 and LSAMP,
with associations of genome-wide significance for UC. We detected SNPs at USP25 with
associations of genome-wide significance associations for IBD. No associations of
genome-wide significance were detected for CD. In addition, 9 genes previously
associated with IBD contained SNPs with significant evidence for replication
(P<1.6×10−6): ADCY3, CXCR6, HLA-DRB1 to HLA-DQA1 (genome-wide
significance on conditioning), IL12B, PTGER4, and TNC for IBD; IL23R, PTGER4, and SNX20
(in strong linkage disequilibrium with NOD2) for CD; and KCNQ2 (near TNFRSF6B) for UC.
Several of these genes, such as TNC (near TNFSF15), CXCR6, and genes associated with IBD
at the HLA locus, contained SNPs with unique association patterns with African-specific
alleles.
Conclusions
We performed a genome-wide association study of African Americans with IBD and
identified loci associated with CD and UC in only this population; we also replicated
loci identified in European populations. The detection of variants associated with IBD
risk in only people of African descent demonstrates the importance of studying the
genetics of IBD and other complex diseases in populations beyond those of European
ancestry.
Background-Patients with inflammatory bowel disease (IBD) are at increased risk of developing colorectal cancer. Aberrant microRNA (miRs) expression has been linked to carcinogenesis, however no reports document a relationship between IBD-related neoplasia (IBDN) and altered miR expression. In the current study we sought to identify specific miR dysregulation along the normal-inflammation-cancer axis.
MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene and protein expression. miRNAs are critical to a normal immune response and have altered expression in multiple immune-mediated disorders. This emerging role of miRNAs in the pathogenesis of multiple disease states has led to investigations into miRNA expression profiles in inflammatory bowel disease (IBD). The discovery of miRNAs in IBD is likely to contribute to our understanding of IBD pathogenesis and lead to clinical advances in IBD. This review focuses on miRNA expression in inflammation, autoimmune disorders, and inflammation-associated cancer, as well as their function in the biology and management of IBD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.